What's in Hui-Sheng Chen's pipeline?

Hui-Sheng Chen has 5 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Hui-Sheng Chen's portfolio?

Top competitors by shared drug class: Cedars-Sinai Medical Center, The University of Texas Health Science Center, Houston.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hui-sheng-chen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Hui-Sheng Chen — Portfolio Competitive Intelligence Brief

Hui-Sheng Chen pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Butyphthalide combined with rtPA	Butyphthalide combined with rtPA	marketed
Argatroban combined with rt-PA	Argatroban combined with rt-PA	marketed
rtPA	rtPA	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Plasminogen; fibrin	Cardiovascular; Neurology

Therapeutic area mix

Cardiovascular; Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Cedars-Sinai Medical Center · 1 shared drug class
The University of Texas Health Science Center, Houston · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hui-Sheng Chen:

Cite this brief

Drug Landscape (2026). Hui-Sheng Chen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hui-sheng-chen. Accessed 2026-05-14.